All Posts Tagged With: "LLY"
(ABT) Abbott Laboratories Earns FDA Approval of AndroGel
Abbott Laboratories (ABT) recently gained US Food and Drug Administration (FDA) approval for AndroGel (testosterone gel) 1.62%. The gel formulation is approved for the treatment of hypogonadism (low or zero...
(HSP) Hospira Earnings Beat The Street – Backs Outlook
Hospira Inc. (HSP) reported earnings per share of 93 cents for the first quarter of 2011, well above the Zacks Consensus Estimate of 79 cents. Earnings benefited from strong US sales of the generic version...
(NVS) Novartis Posts Solid First Quarter Sales
Novartis (NVS) reported earnings per share of $1.41 for the first quarter of 2011, below the year-earlier earnings of $1.45 per share but well ahead of the Zacks Consensus Estimate of $1.31. The drop from...
(AMGN) Amgen Beats First Quarter Estimates – Maintains Outlook
Amgen (AMGN) reported first quarter earnings per share of $1.32, 3 cents above the Zacks Consensus Estimate of $1.29 and 3.1% above year-ago earnings. Higher revenues, a lower tax rate and lower share count...
(MRK) Five Large Cap Pharmaceuticals to Consider
The Large Cap Pharma sector is the fastest rising sector on Barchart when screening for the 1 month price change. The general investing public is very interested in this sector as evidenced by the 25,409 opinions expressed on Motley Fool on the 5 stocks I selected. Before...
(AMLN) Amylin Pharmaceuticals Reports Earnings Loss In-Line with Estimates
Amylin Pharmaceuticals (AMLN) reported a net loss of 24 cents per share in the first quarter of 2011, in line with the Zacks Consensus Estimate and 3 cents below the year-ago loss of 27 cents. Despite a decline...
(AMLN) Amylin Pharmaceuticals, Eli Lilly, and Alkermes Get Positive Opinion for Bydureon
Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (
18Apr2011 | vitalstocks | 0 comments | Continued(ALKS) Company News for April 18, 2011 – Corporate Summary
• Chesapeake Energy Corp’s. (NYSE:CHK) share prices gained 0.25% after it announced plans to buy Bronco Drilling Co. (NASDAQ:BRNC) for $11 a share. The purchase...
(FRX) Forest Labs Fourth Quarter 2011 Earnings Preview
Forest Labs (FRX) is all set to announce its fourth quarter and fiscal 2011 results on April 19. The Zacks Consensus Estimate for the fourth quarter is $1.07, representing a year-over-year...
(UNP) U.S. Trade Deficit Down Slightly
The Trade Deficit fell in February to $45.76 billion from $46.99 billion in January (revised up from $46.34 billion). The fall in the trade deficit is good news for the economy, but the level is still very dangerous.
For the month is was down 2.6%, and it was in line...
(SHPGY) Shire and Watson Pharmaceuticals in Patent Legal Battle
The legal tussle between Shire (SHPGY) and Watson Pharmaceuticals Inc. (WPI) intensified with the Ireland based Shire filing a case of...
(LLY) Eli Lilly’s Axiron Testosterone Deficiency Drug Launched in the U.S.
Eli Lilly and Company (LLY) recently announced the availability of Axiron in pharmacies across the US. Axiron gained approval from the US Food and Drug Administration (FDA) in November 2010 for use as a replacement...
(AMGN) Amgen Appeals EU Drug Opinion
Amgen (AMGN) is appealing the negative recommendation issued by the Committee for Medicinal Products for Human Use (CHMP) for the use of Vectibix plus chemotherapy in patients with wild-type KRAS metastatic...
(AMLN) Amylin Pharmaceuticals Analyst Reports Neutral on Shares
We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). The company reported a net loss of $0.94 per share in 2010, narrower than the Zacks Consensus Estimate of $1.26 and...
(AMLN) Amylin Pharmaceuticals Releases Disappointing Data
Shares of Amylin Pharmaceuticals, Inc. (AMLN) lost more than 25% when the company released disappointing data on Bydureon (exenatide once-weekly) from a head-to-head study. Bydureon failed to achieve its...
(UNP) U.S. Trade Deficit Turns Ugly
The Trade Deficit rose in January to $46.34 billion from $40.26 billion in December (revised down from $40.58 billion). The rise in the trade deficit is very bad news for the economy. Not only did it soar by 15.1% on the month, it was also much worse than the $41.50 billion...
(JNJ) Pharmaceutical Industry Outlook – March 2011 – Industry Outlook
The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
(LLY) Report Shows U.S. Trade Deficit Rose in December As Expected
The Trade Deficit rose in December to $40.58 billion from $38.32 billion in November. The rise in the trade deficit is bad news for the economy. On the other hand, the trade deficit was in line with the $40.40 billion consensus expectation.
On a year-over-year basis,...
(AMZN) Company News for January 28, 2011 – Corporate Summary
• Microsoft (NASDAQ:MSFT) reported Q2 EPS of $0.77, above the Zacks Consensus Estimate of $0.55 per share. Revenues for the quarter were $19.95 billion, well above the Zacks Consensus Estimate of $16.073 billion
• Amazon.com...
(SIGA) These Healthcare Stocks Are Ready to Move Next Week
by Marc Lichtenfeld, Investment U’s Senior Analyst
Wednesday,...
(AMLN) Amylin Pharmaceuticals Analyst Maintains Neutral
We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). Amylin reported a net loss of $0.31 per share in the third quarter of 2010, three cents below the Zacks Consensus...
(LLY) Eli Lilly and Company Gets FDA Approval of Axiron
Eli Lilly and Company (LLY) and partner Acrux recently announced good news in the form of US Food and Drug Administration (FDA) approval for Axiron. The FDA approved Axiron for use as a replacement therapy...
(BMS) Company News for November 24, 2010 – Corporate Summary
• Eli Lilly (NYSE:LLY) received FDA approval for its topical solution drug Axiron, for testosterone replacement therapy in men
• Tiffany (NYSE:TIF) reported estimate-beating third quarter earnings of $0.43 a share, ahead of Zacks projections of $0.37, on a 14%...
(ALKS) Alkermes 2010 Second Quarter Revenues Rise – View Lowered
Alkermes Inc.’s (ALKS) second quarter fiscal 2011 net loss (excluding special items) of 6 cents per share compared unfavorably with the year-ago loss of 5 cents per share. The Zacks Consensus Estimate was...
(INCY) Incyte Loss Smaller Than Forecast – Revenues Strong
Incyte Corporation (INCY) suffered a loss of 26 cents per share in the third quarter of 2010. Loss in the reported quarter was narrower than the Zacks Consensus Estimate of a loss of 33 cents and the year-ago...
(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
(AMLN) Amylin Pharmaceuticals Reports Wider Loss
Amylin Pharmaceuticals (AMLN) reported a net loss of 31 cents per share in the third quarter of 2010, three cents below the Zacks Consensus Estimate but well above the year-earlier loss of 19 cents. Lower...
(JCP) Activist Investors: Follow the Smart Money And Grab an Extra 21% Per Year
by Marc Lichtenfeld, Investment U’s Senior Analyst
Wednesday,...
(GS) How to Unlock Gains From Corporate America
by Marc Lichtenfeld, Investment U’s Senior Analyst
Wednesday,...
(CVD) Big Pharmaceutical Companies Outsourcing Research and Development
by Tony D’Altorio, Investment U Research
Thursday, October 14, 2010
Big...